Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL6793854 | 0.91 | CTSS (0.37) | CTSSMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6800539 | 0.88 | PRMT5 (0.36) | CTSSPRMT5WDR77 | |
| SCHEMBL6794518 | 0.87 | PLK1 (0.36) | CTSSMEN1KMT2AALDH1A1PRMT5 | |
| SCHEMBL6787013 | 0.85 | PRMT5 (0.38) | CTSSALDH1A1PRMT5WDR77 | |
| Trifluoroacetic Acid SCHEMBL6794707 | 0.85 | CTSS (0.37) | CTSS | |
| Hydrochloric Acid SCHEMBL6794118 | 0.84 | CTSS (0.38) | CTSSALDH1A1PRMT5WDR77MAPT | |
| Trifluoroacetic Acid SCHEMBL6787093 | 0.81 | MCHR2 (0.34) | CTSSALDH1A1CFTR | |
| SCHEMBL6792094 | 0.81 | PRMT5 (0.38) | CTSSPRMT5WDR77 | |
| SCHEMBL6792457 | 0.79 | AGER (0.36) | MEN1KMT2A | |
| Lithium Ion SCHEMBL6800533 | 0.79 | PRMT5 (0.35) | CTSSPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CTSS 3602/4885MEN1 1382/4885KMT2A 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.